View Older Stories View More Recent Stories
-
Stifel: 'MRK Acquisition of VRNA Should Broaden Opportunity for Ohtuvayre – A Core LGND Growth Driver'
-
Merck to acquire Verona Pharma for $10 billion to add COPD treatment
-
Certara (CERT) expands clinical technology collaboration with Merck
-
Merck to present HIV research data at IAS 2025 conference
-
UBS Reiterates Buy Rating on Merck (MRK)
-
Merck (MRK) Granted FDA Priority Review for WINREVAIR to Update Label Based on Results From ZENITH Trial
-
TD Cowen on Merck (MRK): 'Enflonsia ACIP Vote Could Unlock Significant Potential'
-
Merck (MRK) Reports ACIP Recommended Use of ENFLONSIA for Prevention of RSV Lower Respiratory Tract Disease in Infants Younger than 8 Months
-
Rfk Jr.'s Vaccine Panel Backs Merck's (MRK) Shot To Prevent RSV
-
Morgan Stanley Reiterates Equalweight Rating on Merck (MRK)
-
Merck (MRK) Announces Phase 3 HYPERION Study of WINREVAIR Met Primary Endpoint
-
Merck (MRK) Gains, CDC Vaccine Panel Will Review MMRV Vaccine Use In Kids Under 5
-
Jefferies: 'We highlight multiple de-risked or commercial-stage names that we think have promising M&A potential'
-
Merck (MRK) Announces FDA Approval of KEYTRUDA for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment
-
Merck (MRK) Animal Health Receives EU CVMP Positive Opinion for NUMELVI Tablets for Dogs
-
Merck (MRK) Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate
-
BMO Capital: ACIP Cuts a Broad Negative To the Vaccine Space
-
Bernstein Reiterates Market Perform Rating on Merck (MRK) Following 'A Positive Event'
-
Cantor Fitzgerald Reiterates Neutral Rating on Merck (MRK)
-
U.S. FDA Approves Merck’s (MRK) ENFLONSIA for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season
-
Merck (MRK) Reports Positive Topline Results From the First Two Phase 3 CORALreef Trials
-
BMO Capital on Merck (MRK): 'Long-Term Plan, Short-Term Challenges'
-
Goldman Sachs Reiterates Buy Rating on Merck (MRK)
-
Merck (MRK) Held Talks To Buy MoonLake Immunotherapeutics (MLTX) - FT
-
Merck (MRK) Announces MK-1084 Shows Antitumor Activity in Phase 1 Trial of Patients With Advanced Colorectal Cancer and Non-Small Cell Lung Cancer Whose Tumors Harbor KRAS G12C Mutations
-
Merck's (MRK) Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate
-
Citizens JMP shares updates on cancer treatment stocks
-
Merck (MRK) Declares $0.81 Quarterly Dividend; 4.2% Yield
-
What can get the U.S. large-cap pharma sector to work?
-
Merck's (MRK) EMD Serono to present new oncological data at ASCO 2025
-
Merck's (MRK) EMD Serono announces positive Enpatoran data
-
UBS Reiterates Buy Rating on Merck (MRK)
-
IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
-
Merck (MRK) Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival
-
Merck (MRK) announces FDA approval of WELIREG
-
Citi Downgrades Merck (MRK) to Neutral
-
Evercore ISI Reiterates Outperform Rating on Halozyme Therapeutics (HALO)
-
Trump to pitch sweeping Medicare drug price plan - Politico
-
Merck (MRK) call put ratio 1 call to 1.3 puts
-
What is the impact of U.S. tariffs on biopharma sector?
-
Kuehn Law Encourages Investors of Merck & Co., Inc. to Contact Law Firm
-
WHO to Back Use of Weight-loss Drugs for Adults Globally, Raises Cost Issue - Reuters
-
Amazon (AMZN) Comments Circulate
-
Merck (MRK) PT Lowered to $108 at Guggenheim
-
Merck (MRK) Breaks Ground on New $1B Biologics Center of Excellence in Wilmington, Delaware
-
Merck to Spend $1 Billion on New Factory to Make US Supplies of Blockbuster Drug - WSJ
-
Merck Kgaa To Buy Springworks For $47 Per Share In Cash- Bloomberg
-
Halozyme Therapeutics (HALO) Sues Merck (MRK) for Patent Infringement over Subcutaneous Keytruda Formulation
-
Merck (MRK) Tops Q1 EPS by 8c; updates guidance
-
Merck & Co. Q1 preview: Here’s what Wells Fargo expects to see
